PCV-2 VACCINE

• US 20110064765A1
• Filed: 12/11/2009
• Published: 03/17/2011
• Est. Priority Date: 09/09/2005
• Status: Active Grant

• Current Assignee: Intervet International BV (Merck & Co., Inc.)
• Original Assignee: Intervet International BV (Merck & Co., Inc.)
• Inventors: Roerink, Frank, Van Woensel, Peter
• Granted Patent: US 8,008,001 B2
• Time in Patent Office: Days
• US Class Current: 424/200.1
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/55511 Organic adjuvants
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. It has been found that a vaccine comprising at least 20 microgram/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2 is capable of eliciting a protective immune response against PCV-2 (and thus against PMWS) even when they have a relatively high titer of MDA against PCV-2.

A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.

Claims

1-9. -9. (canceled)

17. A method for the protection of piglets that are Porcine circovirus type 2 (PCV-2) maternally derived antibody (MDA) positive against PCV-2 infection, comprising administering a vaccine comprising at least 20 micrograms/dose of ORF-2 protein of PCV-2.

10. The method according to claim 17, comprising at least 50 micrograms/dose of ORF-2 protein of porcine circovirus type 2 (PCV-2)

11. The method according to claim 17, wherein the ORF-2 protein is a recombinant protein.

12. The method according to claim 17, wherein the ORF-2 protein is produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.

13. The method according to claim 12, wherein the promoter is the p10 promoter.

14. The method according to claim 17, wherein the vaccine further comprises a suitable adjuvant.

15. The method according to claim 14, wherein the adjuvant is an oil in water emulsion.

16. The method according to claim 14, wherein the adjuvant contains vitamin E.